To develop nonacidic, nonsteroidal anti-inflammatory agents without GI complications, a series of asymmetric triazines was synthesized and evaluated for anti-inflammatory efficacy in the carrageenan-induced pedal edema assay. Toxicity was estimated by determination of approximate LD50 values in mice. Twenty-five compounds possessed activity comparable to the standard, indomethacin. Thirteen of the 25 compounds were selected for dose-response evaluation in the carrageenan assay based on their relative toxicity and anti-inflammatory activity. Neurotoxicity of the 13 triazines was estimated by determination of NTD50 values in mice. Five of the 13 compounds tested in the dose-response assay were active in terms of anti-inflammatory efficacy (ED50 values) and lack of overt neurotoxicity (NTD50 values) when compared to indomethacin. To determine the effect of these five developmental triazines on chronic inflammation, they were evaluated in the adjuvant-induced polyarthritis assay. One was comparable to indomethacin in reducing adjuvant-induced inflammation in this assay.